Mayong its a curious thing to see you only recently joined...

Mayong its a curious thing to see you only recently joined Hotcopper and have done 4 posts all on PAA.

These recent results, although early stage, can not be underestimated. The fact that we have seen a reduction in tumour marker in those first four patients will mean that recruiting further patients will become easier. It follows that these terminally ill patients who have failed all available therapies will be buoyed by these results as we are.
Further results like these in more patients will seriously put a rocket through this company's share price. Remember that the dose will be increased twice in the patients to come.
At this price, you can not knock the value in this company. Just watch this space

Let's not forget Dog trials...